Acute Toxicity and Histopathological Evaluation of Polyherbal Formulations of Annona Squamosa, Zingiber Officinalis and Triticum Aestivum in Wistar Rats

Abstract

The relationship between dose and its effects on the exposed organism is of high significance in toxic evaluation. The present study was aimed for the safety assessment of methanolic extract of Annona squamosa, Zingiber Officinalis and Triticum aestivum as polyherbal formulations at different ratios in albino Wistar rats. Sighting study was conducted in one female rat by administering 300 mg/kg body weight of polyherbal formulation through oral gavage. There were no clinical signs noticed in Sighting study Step I. Sighting study Step II was conducted in another female rat by administering 2000 mg/kg body weight. The animal did not reveal any clinical signs of toxicity and no mortality occurred in all polyherbal formulations for 24 h. Hence the main study was conducted in another set of four female rats by administering a dose of 2000 mg/kg body weight of test item through oral gavage as a single dose. All the animals were observed for 15 days and did not reveal any clinical signs of toxicity and mortality. There were no treatment-related changes observed in body weights and body weight gain up to 2000 mg/kg body weight, no external and internal gross pathological changes and no histopathological changes during the necropsy of animals were noticed. The results have revealed that all the three polyherbal formulations were well tolerated up to a maximum dose of 2000 mg/kg with no observed adverse effects and could be considered as nontoxic in acute ingestion. It also indicated that the LD₅₀ lies at >2000 mg/kg body weight.

Keywords: Acute oral toxicity, polyherbal, Annona squamosa, Zingiber officinalis, Triticum aestivum

Cite this Article

R. Rajesh, S. D. Jagadeesh Singh, R. Channabasava. Acute Toxicity and Histopathological Evaluation of Polyherbal Formulations of Annona Squamosa, Zingiber Officinalis and Triticum Aestivum in Wistar Rats. Research & Reviews: A Journal of Drug Design & Discovery. 2019; 6(3): 1–7p.